Simulations Plus Announces Global Pharmaceutical Software Order; Another Large Pharmaceutical Company Signs Global License
Simulations Plus, Inc. (AMEX:SLP), the leading provider of ADMET absorption simulation and neural net structure-to-property prediction software for pharmaceutical discovery and development, announced that it received a large multi-site order for software licenses from a major pharmaceutical company. Financial details were not disclosed.
Ron Creeley, vice president of marketing and sales of Simulations Plus, said: “We are pleased to announce that a top-five pharmaceutical company has signed a one-year global subscription agreement to expand its number of licenses for our GastroPlus(TM) software to six of its research sites in the U.S., Europe, and Japan. GastroPlus simulates absorption and pharmacokinetics for orally dosed drugs. This order represents this company’s first step in providing Simulations Plus’ software tools to its research scientists worldwide. We believe this customer intends to turn this one-year agreement into a multi-year global contract that may include our other software product lines such as ADMET Predictor(TM) (formerly QMPRPlus(TM)) and ADMET Modeler(TM) (formerly QMPRchitect(TM)). We expect to also see licenses for these packages in the near future.”
Walt Woltosz, chairman and chief executive officer of Simulations Plus, commented: “This order, which was received at the end of our first quarter, is one we’ve been working on for some time. We’re pleased that the customer has committed to a one-year global license of GastroPlus. We hope to transition this customer in the future to our ADMET Partners(TM) program, which is a software licensing program developed by us to provide clients cost-effective, multiple-location site licenses with unlimited access to all our software programs.”
About Simulations Plus, Inc.
Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development simulation software, which is licensed to and used in the conduct of drug research by major pharmaceutical and biotechnology companies worldwide. The Company has two other businesses, Words+, Inc. and FutureLab(TM), which are based on its proprietary software technologies. Simulations Plus, Inc., is headquartered in Southern California. For more information, visit our Web site at http://www.simulations-plus.com .
